CA-074 methyl ester
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- CA-074 methyl ester
- DrugBank Accession Number
- DB07223
- Background
CA-074 methyl ester (CA-074Me) is a cell-permeable cathepsin B inhibitor. It is converted by cellular esterases to CA-074.1,2
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 397.4659
Monoisotopic: 397.221285739 - Chemical Formula
- C19H31N3O6
- Synonyms
- (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate
- CA 074 Me ester
- CA 074 methyl ester
- L-Proline, 1-[N-[[3-[(propylamino)carbonyl]oxiranyl]carbonyl]-L-isoleucyl]-, methyl ester, (2S-trans)-
- L-Proline, N-[[(2S,3S)-3-[(propylamino)carbonyl]oxiranyl]carbonyl]-L-isoleucyl-, methyl ester
- Methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate
- Methyl N-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-isoleucyl-L-prolinate
- External IDs
- CA 074Me
- CA-074 Me
- CA-074Me
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCathepsin B Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Peptides
- Alternative Parents
- Isoleucine and derivatives / Alpha amino acid esters / Proline and derivatives / N-acyl-alpha amino acids / Alpha amino acid amides / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Oxirane carboxylic acids and derivatives / Methyl esters / Tertiary carboxylic acid amides show 10 more
- Substituents
- Aliphatic heteromonocyclic compound / Alpha peptide / Alpha-amino acid amide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid ester / Dialkyl ether show 24 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 147859-80-1
- InChI Key
- XGWSRLSPWIEMLQ-YTFOTSKYSA-N
- InChI
- InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1
- IUPAC Name
- methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate
- SMILES
- [H][C@](C)(CC)[C@]([H])(NC(=O)[C@@]1([H])O[C@]1([H])C(=O)NCCC)C(=O)N1CCC[C@@]1([H])C(=O)OC
References
- General References
- Yoon MC, Christy MP, Phan VV, Gerwick WH, Hook G, O'Donoghue AJ, Hook V: Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B. Biochemistry. 2022 Feb 15;61(4):228-238. doi: 10.1021/acs.biochem.1c00684. Epub 2022 Feb 4. [Article]
- Jane DT, Morvay LC, Allen F, Sloane BF, Dufresne MJ: Selective inhibition of cathepsin B with cell-permeable CA074Me negatively affects L6 rat myoblast differentiation. Biochem Cell Biol. 2002;80(4):457-65. doi: 10.1139/o02-134. [Article]
- External Links
- PubChem Compound
- 6610318
- PubChem Substance
- 99443694
- ChemSpider
- 5042571
- BindingDB
- 16503
- ChEMBL
- CHEMBL262103
- ZINC
- ZINC000004899858
- PDBe Ligand
- 74M
- PDB Entries
- 2dc9
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.9 mg/mL ALOGPS logP 0.76 ALOGPS logP 0.31 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 12.2 Chemaxon pKa (Strongest Basic) -3.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 117.34 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 99.34 m3·mol-1 Chemaxon Polarizability 41.92 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8421 Blood Brain Barrier - 0.7765 Caco-2 permeable - 0.6654 P-glycoprotein substrate Substrate 0.7129 P-glycoprotein inhibitor I Inhibitor 0.5386 P-glycoprotein inhibitor II Inhibitor 0.506 Renal organic cation transporter Non-inhibitor 0.9269 CYP450 2C9 substrate Non-substrate 0.9096 CYP450 2D6 substrate Non-substrate 0.8197 CYP450 3A4 substrate Substrate 0.5243 CYP450 1A2 substrate Non-inhibitor 0.7625 CYP450 2C9 inhibitor Non-inhibitor 0.775 CYP450 2D6 inhibitor Non-inhibitor 0.8701 CYP450 2C19 inhibitor Non-inhibitor 0.7213 CYP450 3A4 inhibitor Inhibitor 0.5831 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7654 Ames test Non AMES toxic 0.6917 Carcinogenicity Non-carcinogens 0.8652 Biodegradation Not ready biodegradable 0.8975 Rat acute toxicity 2.4300 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9853 hERG inhibition (predictor II) Non-inhibitor 0.7976
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-1219000000-8bd6c5161472ad382789 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-01ta-2719000000-b50dab23412673e9725a Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0532-9747000000-f0ea66e0224c73404b0e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03fs-7967000000-80fc8ed7fec070a5ce79 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0pi4-9432000000-a7f3018685fe556a184d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-002f-9701000000-2320f4ca301d5c991de0 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 190.21602 predictedDeepCCS 1.0 (2019) [M+H]+ 192.04091 predictedDeepCCS 1.0 (2019) [M+Na]+ 197.64673 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCathepsin B
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Thiol protease which is believed to participate in intracellular degradation and turnover of proteins (PubMed:12220505). Cleaves matrix extracellular phosphoglycoprotein MEPE (PubMed:12220505). Involved in the solubilization of cross-linked TG/thyroglobulin in the thyroid follicle lumen (By similarity). Has also been implicated in tumor invasion and metastasis (PubMed:3972105)
- Specific Function
- collagen binding
- Gene Name
- CTSB
- Uniprot ID
- P07858
- Uniprot Name
- Cathepsin B
- Molecular Weight
- 37821.35 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:19 / Updated at March 14, 2023 09:13